Franz-Werner Haas, CureVac CEO (Christoph Schmidt/picture-alliance/dpa/AP Images)
January 30, 2023 11:27 AM EST
R&D

Cure­Vac touts old­er adult da­ta for GSK-part­nered Covid-19, flu can­di­dates

Paul Schloesser

Associate Editor

Ger­many’s Cure­Vac re­port­ed da­ta Mon­day on old­er pa­tients to beef up plans to ad­vance vac­cines for Covid-19 and sea­son­al flu.

In short, the Covid-19 da­ta …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times